FDA Approves Torisel for Renal Cell Carcinoma

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

FDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa

ROCKVILLE, Maryland—FDA has approved Wyeth's Torisel (temsirolimus) for the treatment of advanced renal cell carcinoma, based on a study showing prolonged survival with Torisel as a single agent vs interferon alfa. Median overall survival was 10.9 months for Torisel patients vs 7.3 months for interferon patients. Progression-free survival increased from 3.1 months with interferon to 5.5 months with Torisel. The combination of Torisel and interferon did not result in a significant increase in overall survival, compared with interferon alone. Look for a complete report on the approval in the July issue of ONI.

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Related Content